| HUMAN-TRIAL | evidence | Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. | Ipamorelin | Gut barrier & GI healing · human-rct · n = 117 | 2014-12-01 |
| HUMAN-TRIAL | evidence | Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. | Ipamorelin | Growth hormone axis · human-rct · n = 40 | 1999-09-01 |
| HUMAN-TRIAL | evidence | Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function | Ipamorelin | Gut barrier & GI healing · human-rct · n = 320 | — |
| HUMAN-TRIAL | evidence | Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus | Ipamorelin | human-rct · n = 117 | — |
| REGULATORY | regulatory | D-0777-2022 — Ipamorelin Acetate/Sermorelin Acetate (1 mg/1 mg)/mL (10 mL) Injection, 10 mL vials, Rx Only, Farmakeio 1736 N Greenville Ave Richardson, TX 75081 | FDA | — | 2022-04-05 |
| REGULATORY | regulatory | D-0144-2022 — SERMORELIN ACETATE 6MG/IPAMORELIN 6MG - LYOPHILIZED 6MG/6MG VIAL, Rx only, Talon Compounding Pharmacy, 2950 Thousand Oaks Drive Ste 25, San Antonio, Texas 78247 | FDA | — | 2021-10-12 |
| REGULATORY | regulatory | D-0143-2022 — SERMORELIN ACETATE 15MG/IPAMORELIN 15MG - LYOPHILIZED 15MG/15MG VIAL, Rx only, Talon Compounding Pharmacy, 2950 Thousand Oaks Drive Ste 25, San Antonio, Texas 78247 | FDA | — | 2021-10-12 |
| REGULATORY | regulatory | D-0145-2022 — SERMORELIN ACETATE 9MG/IPAMORELIN 9MG - LYOPHILIZED 9MG/9MG VIAL, Rx only, Talon Compounding Pharmacy, 2950 Thousand Oaks Drive Ste 25, San Antonio, Texas 78247 | FDA | — | 2021-10-12 |
| REGULATORY | regulatory | D-0109-2022 — CJC-1295 4MG/IPAMORELIN 4MG VIAL 4MG/4MG INJECTABLE, Rx only, Talon Compounding Pharmacy, 2950 Thousand Oaks Drive Ste 25, San Antonio, Texas 78247 | FDA | — | 2021-10-12 |
| REGULATORY | regulatory | D-0692-2021 — Compounded Lyophilized Semorelin/Ipamorelin 3 mg For subcutaneous or intramuscular injection, Rx Only, Compounded by: Innoveix Addison, TX 75001 800-370-1910 | FDA | — | 2021-07-09 |
| REGULATORY | regulatory | D-0134-2021 — IPAMORELIN, 2000 MCG/ML, 5 ML vial, The Guyer Institute of Molecular Medicine, Indianapolis, IN | FDA | — | 2020-11-30 |
| REGULATORY | regulatory | D-0748-2020 — IPAMORELIN 2000MCG/ML INJ in 2 mL vial Assurance Infusion (713) 533-8800 | FDA | — | 2019-12-20 |
| REGULATORY | regulatory | D-0720-2020 — CJC-1295 2000 mcg/Ipamorelin 2000 mcg/mL Inj. in 2 mL vial Assurance Infusion (713) 533-8800 | FDA | — | 2019-12-20 |
| REGULATORY | regulatory | D-1330-2019 — Sermorelin/Ipamorelin 18 mg/15 mg, 10mL vials, Rx only, Pharm D. Solutions 1304 South Loop West, Houston, TX 77054, 1-844-263-6846 | FDA | — | 2019-05-23 |
| REGULATORY | regulatory | D-1327-2019 — Ipamorelin Acetate 9 mg/9mL Injectable vials, Rx only, Pharm D. Solutions 1304 South Loop West, Houston, TX 77054, 1-844-263-6846 | FDA | — | 2019-05-23 |
| REGULATORY | regulatory | D-0455-2019 — Ipamorelin, 15mg, injection, Rx Only, Promise Pharmacy Compounding Specialists 31818 US Hwy 19N, Palm Harbor, FL 34684 | FDA | — | 2018-12-17 |
| REGULATORY | regulatory | D-0453-2019 — Ipamorelin, 9 mg injection, Rx Only, Promise Pharmacy Compounding Specialists 31818 US Hwy 19N, Palm Harbor, FL 34684 | FDA | — | 2018-12-17 |
| REGULATORY | regulatory | D-0454-2019 — Ipamorelin+Sermorelin, 15mg/15mg, injection, Rx Only, Promise Pharmacy Compounding Specialists 31818 US Hwy 19N, Palm Harbor, FL 34684 | FDA | — | 2018-12-17 |
| REGULATORY | regulatory | D-0452-2019 — Ipamorelin+Modified GRF 1-29, 9 mg/5mg injection, Rx Only, Promise Pharmacy Compounding Specialists 31818 US Hwy 19N, Palm Harbor, FL 34684 | FDA | — | 2018-12-17 |
| REGULATORY | regulatory | D-0179-2019 — Sermorelin/Ipamorelin 18 mg/15 mg Powder, Pharm D Solutions, Houston, Texas --- NDC 69699-1759-18 | FDA | — | 2018-09-10 |
| REGULATORY | regulatory | D-1153-2018 — Ipamorelin 3 mg Lyophilized 1 vial 1109 East Hallandale Beach Blvd. Hallandale Beach, FL 33009 | FDA | — | 2018-08-02 |
| REGULATORY | regulatory | D-1155-2018 — Ipamorelin 9 mg vial Lyophilized 1109 East Hallandale Beach Blvd. Hallandale Beach, FL 33009 | FDA | — | 2018-08-02 |
| ANIMAL | evidence | The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism. | Ipamorelin | Weight & fat loss · animal | 2024-10-01 |
| ANIMAL | evidence | The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus. | Ipamorelin | animal | 2024-09-01 |
| ANIMAL | evidence | Doping control analysis of seven bioactive peptides in horse plasma by liquid chromatography-mass spectrometry. | Ipamorelin | animal | 2013-03-01 |
| ANIMAL | evidence | Metabolism of growth hormone releasing peptides. | Ipamorelin | Growth hormone axis · animal | 2012-12-04 |
| ANIMAL | evidence | Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats. | Ipamorelin | Growth hormone axis · animal | 2009-10-01 |
| ANIMAL | evidence | Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. | Ipamorelin | Gut barrier & GI healing · animal | 2009-06-01 |
| ANIMAL | evidence | Seabream ghrelin: cDNA cloning, genomic organization and promoter studies. | Ipamorelin | Growth hormone axis · animal | 2006-05-01 |
| ANIMAL | evidence | Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. | Ipamorelin | Glycemic control · animal | 2004-12-01 |
| ANIMAL | evidence | Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro. | Ipamorelin | Growth hormone axis · animal | 2002-01-01 |
| ANIMAL | evidence | The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. | Ipamorelin | Muscle growth & preservation · animal | 2001-10-01 |
| ANIMAL | evidence | Do growth hormone-releasing peptides act as ghrelin secretagogues? | Ipamorelin | Growth hormone axis · animal | 2001-02-01 |
| ANIMAL | evidence | Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. | Ipamorelin | Weight & fat loss · animal | 2001-01-12 |
| ANIMAL | evidence | The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. | Ipamorelin | animal | 2000-06-01 |
| ANIMAL | evidence | Methylprednisolone does not inhibit the release of growth hormone after intravenous injection of a novel growth hormone secretagogue in rats. | Ipamorelin | Growth hormone axis · animal | 1999-12-01 |
| ANIMAL | evidence | Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. | Ipamorelin | animal | 1999-04-01 |
| ANIMAL | evidence | Ipamorelin, the first selective growth hormone secretagogue. | Ipamorelin | Growth hormone axis · animal | 1998-11-01 |
| ANIMAL | evidence | Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. | Ipamorelin | Growth hormone axis · animal | 1998-11-01 |
| ANIMAL | evidence | Novel orally active growth hormone secretagogues. | Ipamorelin | Growth hormone axis · animal | 1998-09-10 |
| PRECLINICAL | evidence | A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. | Ipamorelin | — | 2026-07-01 |
| PRECLINICAL | evidence | Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications. | Ipamorelin | — | 2026-05-01 |
| PRECLINICAL | evidence | Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. | Ipamorelin | — | 2026-04-27 |
| PRECLINICAL | evidence | Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. | Ipamorelin | — | 2026-04-12 |
| PRECLINICAL | evidence | The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. | Ipamorelin | Growth hormone axis | 2026-01-01 |
| PRECLINICAL | evidence | Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. | Ipamorelin | — | 2026-01-01 |
| PRECLINICAL | evidence | Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. | Ipamorelin | — | 2026-01-01 |
| PRECLINICAL | evidence | Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. | Ipamorelin | Wound healing | 2026-01-01 |
| PRECLINICAL | evidence | Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. | Ipamorelin | — | 2020-03-01 |
| PRECLINICAL | evidence | Attenuation of Visceral and Somatic Nociception by Ghrelin Mimetics. | Ipamorelin | — | 2020-01-01 |